Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Stroke, Chronic Stroke Patients, Cerebrovascular Accident (CVA)
Interventions: Device: Q Therapeutic System (BQ 3.0) - Active; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Melanoma
Interventions: CVA21; Biological
Lead sponsor: Viralytics; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Park Ridge, Illinois • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Asthma
Interventions: GW685698X, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 81 more

Conditions: Atopic Dermatitis
Interventions: NM26-2198, Placebo; Biological · Other
Lead sponsor: Yellow Jersey Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fountain Valley, California • Glendale, California • San Diego, California + 3 more

Conditions: Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Interventions: Fabrazyme (agalsidase beta); Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 9
States / cities: Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more

Conditions: SMARD1, CMT2S
Interventions: Gene Therapy; Biological
Lead sponsor: Megan Waldrop; Other
Eligibility: 2 Months to 14 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acute Lymphoblastic Leukemia
Interventions: Ibrutinib, Dasatinib, Prednisone; Drug
Lead sponsor: University of Utah; Other
Eligibility: 60 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: Counseling session, Questionnaire 1, Questionnaire 2, online questionnaire; Behavioral · Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 35 Years to 120 Years · Female only
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions: BIBW 2948 BS; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 5 more

Conditions: Neoplasm Metastases
Interventions: Sequence 1, Sequence 2; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Chronic Diseases
Interventions: smoking cessation; Behavioral
Lead sponsor: National Institutes of Health (NIH); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 443 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Infant Development, Perinatal Stroke, Hemiparesis, Cerebral Palsy
Interventions: Non interventional study; Other
Lead sponsor: Ohio State University; Other
Eligibility: 4 Months to 36 Months
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: filgrastim, pegylated liposomal doxorubicin hydrochloride; Biological · Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Heart Failure
Interventions: MedSentry System; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions: Apixaban, Warfarin; Drug
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Eustachian Tube Dysfunction
Interventions: Balloon dilation of the Eustachian tube; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
Interventions: Mindfulness Based Stress Reduction (MBSR); Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Premature Birth, Basic Learning Problem in Reading, Child
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 57 Months to 78 Months
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Vitamin D Deficiency
Interventions: Prenatal Vitamin, Cholecalciferol (Vitamin D3); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Mild Cognitive Impairment
Interventions: Growth Hormone Releasing Hormone (GHRH), Placebo Growth Hormone Releasing Hormone; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 55 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions: Sirolimus; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ileus
Interventions: chewing gum - Extra Winterfresh, Standard Post-Op Care; Other
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Meningeal Hemangiopericytoma, Adult Papillary Meningioma, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Recurrent Adult Brain Tumor
Interventions: bevacizumab; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 2 more

Search by objective public record fields.

RESPARK - Brain Q for Chronic Stroke

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

Gene Therapy for IGHMBP2-Related Diseases

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Longitudinal Care: Smoking Reduction to Aid Cessation

Behavioral Assessment Method Index

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

The Effect of the MedSentry System on Medication Adherence

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Balloon Dilation in Selected Subjects With Refractory Eustachian Tube Dysfunction

Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

Reading in Preterm and Full-term Children: Neural Basis and Prediction

Ancillary Longitudinal CSF Collection Study in the Harvard Biomarker Study - HBS2

Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

Prevention of Ileus After Gynecologic Surgery Using Chewing Gum

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas